<DOC>
	<DOCNO>NCT00053222</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient locally advance metastatic pancreatic cancer respond gemcitabine .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Pancreatic Cancer That Has Not Responded Gemcitabine</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective response rate arsenic trioxide patient pancreatic cancer progress first-line treatment gemcitabine-containing regimen treat arsenic trioxide . - Determine toxicity drug patient . - Determine duration response , median overall survival , time progression patient treat drug . OUTLINE : This multicenter study . Patients receive arsenic trioxide IV 1 hour day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients follow survival . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 9-12 month .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm adenocarcinoma pancreas Locally advance metastatic disease Unidimensionally measurable disease At least 1 lesion least 20 mm conventional technique least 10 mm spiral CT scan Must progress chemotherapy gemcitabinecontaining regimen No know brain metastasis PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL AST/ALT great 5 time upper limit normal Renal Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular QTc le 500 msec baseline EKG No New York Heart Association class III IV heart failure No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior allergic reaction attribute compound similar chemical biological composition arsenic trioxide No active malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No ongoing active infection No psychiatric illness social situation would preclude study compliance No uncontrolled illness PRIOR CONCURRENT THERAPY : Biologic therapy No concurrent immunotherapy No concurrent colonystimulating factor first course study Chemotherapy See Disease Characteristics At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover No prior arsenic trioxide No concurrent chemotherapy No 1 prior chemotherapy regimen metastatic disease Endocrine therapy No concurrent hormonal therapy Radiotherapy At least 4 week since prior radiotherapy recover No concurrent therapeutic radiotherapy Surgery At least 4 week since major surgery Other No concurrent investigational commercial anticancer agent therapies No concurrent investigational agent No concurrent antiretroviral therapy HIVpositive patient No concurrent medication comorbid condition know prolong QT interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage II pancreatic cancer</keyword>
	<keyword>stage III pancreatic cancer</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>